[Amifampridine (Firdapse) for the treatment of Lambert Eaton Myasthenic Syndrome]

Comite d'Avaluacio de Medicaments d'Utilitzacio Hospitalaria (CAMUH)
Record ID 32010000700
Catalan, English
Authors' objectives:

To assess the efficacy, safety and efficiency of amifampridine as compared to placebo in the treatment of patients with LEMS.

Authors' recommendations: The approval of amifampridine in patients with LEMS is based on previous studies with 3,4-DAP. No additional studies have been carried out for marketing approval. The results indicate that 3,4-DAP in the symptomatic treatment of LEMS at short-term.
Project Status: Completed
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Lambert-Eaton Myasthenic Syndrome
Organisation Name: Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address: Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name: direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email: direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.